Wuhan Dangdai returns with tap

pills adobe stock 575x375 pharmaceuticals
By Alice Huang
06 Jul 2020

Wuhan Dangdai Science & Technology Industries (Group) Co chose a quiet Friday for deal flow to raise $200.5m from a tap.

The Reg S deal marked the Chinese company’s third visit to the offshore bond market. The unrated conglomerate, which mainly operates in the biomedical and pharmaceutical sectors, debuted in the dollar market in 2017 with a $300m 7.25% 2020 bond.

Wuhan Dangdai returned to the market in ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial